Jazz Pharma says FDA approves Ziihera regimens for first-line HER2-positive gastroesophageal adenocarcinoma

• U.S. FDA cleared Ziihera regimens for first-line HER2-positive advanced gastroesophageal adenocarcinoma, with tislelizumab and chemotherapy or with chemotherapy alone.
• Label covers all HER2-positive patients for the tislelizumab regimen, regardless of PD-L1 status; chemo-only use limited to IHC 3+ disease.
• Approval backed by Phase 3 HERIZON-GEA-01 data showing median overall survival of 26.4 months versus 19.2 months for trastuzumab chemotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608251000PR_NEWS_USPR_____SF30755) on August 25, 2026, and is solely responsible for the information contained therein.